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Compensatory renal growth in uninephrectomized adult mice nephrectomy [1–10]. The first published indirect evi-
is growth hormone dependent. dence that the GH/IGF axis may be involved in CRG
Background. Growth hormone (GH) and insulin-like growth arose from studies in which a blunted CRG response wasfactors (IGFs) have been implicated as pathogenic factors in
seen in unilaterally nephrectomized hypophysectomizedcompensatory renal growth (CRG) following unilateral nephrec-
rats [1, 2]. In addition, adults rats exposed to unilateraltomy in rodents. CRG in adult rats has been suggested to be
GH dependent and GH independent in immature rats. How- nephrectomy have been associated with an early increase
ever, the exact role of GH as a regulating or permissive factor in pulsatile GH release [10], and furthermore, the admin-
in CRG in adult rodents has not been fully resolved to date. istration of a long-acting somatostatin analogue (octreo-Methods. To elucidate a possible direct, permissive role of
tide) [6] or a GH-releasing factor antagonist [9] has beenGH in CRG, we examined the effect of a newly developed
shown to abolish the early CRG. Several studies havespecific GH receptor (GHR) antagonist (G120K-PEG) on kid-
ney IGF-I accumulation and renal/glomerular hypertrophy over shown an early rise in extractable or immunoassayable
seven days after uninephrectomy in adult mice. kidney IGF-I content in the remnant kidney following
Results. Placebo-treated uninephrectomized mice were char-
unilateral nephrectomy in adult rats [3, 5–7]. However,acterized by a transient increase in kidney IGF-I concentration
the mechanism responsible for this rise in renal IGF-Ipreceding CRG and an increase in glomerular volume. In
G120K-PEG–treated uninephrectomized animals, increased is still a matter of debate, as different changes in gene
kidney IGF-I levels, kidney weight, and glomerular volume were expression of the IGF axis have been reported in adult
fully abolished. No differences were seen between the two and immature rats during CRG [7–11]. Finally, in adultuninephrectomized groups with respect to body weight, food
rats, CRG has been shown to be GH dependent, whereasintake, blood glucose, serum GH, IGF-I, or IGFBP-3 levels.
the process in immature rats is GH independent [8–11].Conclusions. The administration of a GHR antagonist in
uninephrectomized adult mice has renal effects without affect- Based on these studies, it seems evident that CRG, both
ing circulating levels of GH/IGFs, indicating that the effect of in immature and adult rodents, is IGF dependent; How-
G120K-PEG may be mediated through a direct inhibitory ef-
ever, thus far the precise role of GH in adult rodents asfect on renal IGF-I accumulation through the renal GHR. This
a modulating or strictly permissive factor for CRG hasstudy shows, to our knowledge for the first time, that CRG in
adult mice is strictly GH dependent. not yet been resolved. Recently, a series of highly specific
GH receptor (GHR) antagonists has been developed for
potential therapeutic use [12–18]. Accordingly, the aim
Growth hormone (GH) and insulin-like growth factors of this study was to examine the effect of a specific GHR
(IGFs) have been implicated as pathogenic factors in antagonist (G120K-PEG) on the kidney GH/IGF-I sys-
compensatory renal growth (CRG) following unilateral tem, renal enlargement, and glomerular hypertrophy in
adult mice exposed to unilateral nephrectomy.
Key words: growth hormone, antagonist, nephrectomy, insulin-like
growth factors, mRNA.
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The mice were housed four per cage in a room with a previously described [18, 19]. Briefly, 80 to 100 mg of
tissue were homogenized on ice in 1 m acetic acid (5 ml/g12:12 hour (7:00 a.m. to 7:00 p.m.) artificial light cycle,
a temperature of 21 6 28C, and a humidity of 55 6 2%. tissue) with an Ultra Turrax TD 25 and were further
disrupted using a Potter Elvehjelm homogenizer (bothThe animals had free access to standard chow (Altromin
#1324; Lage, Germany) and tap water throughout the from Janke-Kunkel GmbH, Staufen, Germany). With
this procedure, all IGFBPs were removed from kidneyexperiment. The animals were randomized into four
groups, and two of these groups were exposed to a right- tissue [19]. After lyophilization, the samples were redis-
solved in phosphate buffer (pH 8.0) and kept at 2808Cside nephrectomy for placebo (NP) or GHR antagonist
(NA) treatment. One group was exposed to sham opera- until the IGF-I assay was performed in diluted extracts.
Serum and kidney IGF-I levels were measured by RIAtion (S) by a flank incision with manipulation of the
kidney, whereas the fourth group served as a nonoper- using a polyclonal rabbit antibody (Nichols Institute Di-
agnostics, San Capistrano, CA, USA) and recombinantated control group (C). All operations were performed
under anesthesia with avertin (240 mg/kg body wt i.p.). human IGF-I as the standard (Amersham International).
The kidney tissue IGF-I concentrations were correctedHalf of the animals exposed to unilateral nephrectomy
were treated with subcutaneous injections of a pegylated for the contribution of entrapped serum IGF-I [18, 19].
Monoiodinated IGF-I [125I-(Tyr31)-IGF-I] was obtainedGHR antagonist (G120K-PEG; Sensus, Austin, Texas,
USA) [12–20]. The treatment was started immediately from Novo-Nordisk A/S (Bagsværd, Denmark). The in-
tra-assay and interassay coefficients of variations for bothafter unilateral nephrectomy and was given in a dose of
2 mg/kg body wt every second day to maintain high assays were less than 5% and 10% for both assays.
diurnal levels of the GHR antagonist. The other half of
Western ligand blotting for determination of serumuninephrectomized mice were injected with an equiva-
insulin-like growth factor-binding protein 3lent volume of vehicle (0.154 m NaCl). At days 0, 2,
and 7 during the study, the following parameters were Sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) and Western ligand blotting (WLB)recorded: body weight, blood glucose, and fodder con-
sumption. When animals were taken out for examination were performed according to the method of Hossenlopp
et al [21] as previously described [22]. Two microlitersat days 0 (group C), 2 (groups S, NP, and NA), and 7
(groups S, NP, and NA; N 5 6 in each group at each of serum were subjected to SDS-PAGE (10% polyacryl-
amide) under nonreducing conditions. The electropho-time point), anesthesia was performed with sodium bar-
bital (10 mg/kg body wt i.p.), and blood was drawn ex- resed proteins were transferred by electroelution onto
nitrocellulose paper (Schleicher & Schuell, Munich, Ger-actly five minutes later from the retro-orbital venous
plexus for determination of serum GH, IGF-I, and many), and membranes were incubated overnight at 48C
with approximately 500,000 cpm 125I-IGF-I (specific ac-IGFBP-3. Serum was stored at 2808C until measure-
ments were performed. Furthermore, the left kidneys tivity 2000 Ci/mmol) in 10 ml 10 mmol/liter Tris-HCl
buffer (TBS) containing 1% bovine serum albumin andwere rapidly removed and carefully cleaned and weighed.
A two millimeter thick horizontally cut slice from the 0.1% Tween (pH 7.4). Membranes were washed with
TBS, and after drying overnight, the nitrocellulose sheetsmiddle of the left kidney (including the papilla) was fixed
in 4% paraformaldehyde for morphological measure- were autoradiographed with Kodak X-AR film and ex-
posed to DuPont-New England Nuclear (Boston, MA,ments. Finally, the two remnant pieces of each left kidney
were snap frozen in liquid nitrogen for later determina- USA) enhancing screens at 2808C for three to seven
days. Specificity of the IGFBP bands was ensured bytion of GHR, GH binding protein (GHBP), IGF-I gene-
expression, and IGF-I peptide. competitive coincubation with unlabeled IGF-I pur-
chased from Bachem (Bubendorf, Switzerland). On WLB
Immunoassays (with 125I-IGF-I as ligand), IGFBP-3 appeared as a 38 to
42 kDa doublet band corresponding to the intact acid-Serum GH was measured by radioimmunoassay
(RIA) using a specific polyclonal rabbit rat (r) GH anti- stable IGF-binding subunit of IGFBP-3.
body and rGH as the standard. Semilog linearity of
Northern blotting for determination of kidney GHR,mouse serum and rGH (in the standard) was found at
GHBP, and IGF-I mRNAmultiple dilutions, which is an indication of antigen simi-
larity between mouse GH and rGH. The ingredients, Renal gene expression of GHR, GHBP, and IGF-I
was measured by Northern blot analysis. Total RNAincluding 125I-rGH, were obtained from Amersham Inter-
national (Bucks, UK). Serum IGF-I was measured after was extracted from kidney samples by the guanidinium
thiocyanate method as previously described [23]. Glyoxi-extraction with acid ethanol. The mixture was incubated
for two hours at room temperature and was centrifuged, lated RNA samples were electrophoresed in 1% agarose
gels submerged in 10 mm sodium phosphate, pH 7.2, andand 25 ml of the supernatant were diluted 1:200 before
analysis [18, 19]. Kidney extraction was performed as transferred to nylon membranes (Hybond N1; Amer-
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sham, Hertogenbosch, The Netherlands). Filters were
hybridized with 1 to 2 106 cpm/ml of 32P-labeled cDNA
fragments encoding for GHR/GHBP [24], IGF-I (kindly
provided by Dr. G.I. Bell, Chicago, IL, USA), and 18S
rRNA at 658C according to the method of Church and
Gilbert [25].
Quantitation of gels
Western ligand blots were quantitated by densitome-
try using a Shimadzu CS-9001 PC dual wavelength flying
spot scanner (Shimadzu Europe GmbH, Duisburg, Ger-
many), and the relative densities were expressed as pixel
density. Northern blots were scanned on a Phosphor
Imager (Molecular Dynamics, Sunnyvale, CA, USA)
and quantitated using ImageQuant software. All mea-
sured mRNA results were expressed relative to 18S
rRNA levels as arbitrary units.
Estimation of glomerular volume
A 2 mm thick horizontally cut slice from the middle
of the right kidney (containing the papilla) was fixed in
4% paraformaldehyde and embedded in Technovit. Two
micron thick sections were cut on a rotation microtome
and stained with periodic acid-Schiff stain and hematoxy-
lin. The mean glomerular tuft volume (VG) was determined
from the mean glomerular cross-sectional area (AG) by
light microscopy, as previously described [26, 27]. Profile
areas were traced using a computer-assisted morphomet-
ric unit (Image Tool; The University of Texas Health
Science Center, San Antonio, TX, USA). AG was deter-
mined as the average area of a total of 40 to 80 glomeruli
(tuft omitting the proximal tubular tissue within the Bow-
Fig. 1. Changes over seven days in body weight (A) and food consump-mann capsule) and VG calculated as follows:
tion (B) in nonoperated controls (h), sham-operated animals ( ),
uninephrectomized animals treated with placebo ( ), or G120K-PEGVG 5 b/k 3 (AG)3/2
(2 mg/kg/body wt every second day; j). Values are mean 6 sem (N 5
6 in each group). *P , 0.05 vs. sham-operated group on day 2.where b 5 1.38 is the shape coefficient for spheres (the
idealized shape of glomeruli), and k 5 1.1 is a size distri-
bution coefficient [26, 27].
day 7 (Fig. 1A). Similarly, food consumption (expressed
Statistics as g/24 hr) decreased transiently in both uninephrectom-
Analysis of variance analyses (ANOVA) for repeated ized groups at day 2 (12%, P , 0.05) when compared
measurement were used to evaluate differences in com- with sham-operated animals, whereas no difference was
bination with Student’s t-test for unpaired comparisons. seen on day 7 (Fig. 1B). Again, G120K-PEG treatment
A P value of less than 0.05 was regarded as significant. did not affect the food intake in either group (Fig. 1B).
Means are given 6 sem. No changes in blood glucose levels were seen in any
group at any time point (data not shown).
RESULTS Serum GH, IGF-I, IGFBP-3, and kidney IGF-I
Body weight, food consumption, and blood glucose Figure 2 shows serum GH, IGF-I, and IGFBP-3 levels
Both groups of animals exposed to unilateral nephrec- in the four experimental groups over the study period
tomy (placebo and G120K-PEG treated) had a minor of seven days. It has been shown previously that barbital
decrease (8 to 11%) in body weight two days after opera- anesthesia induces a rise in GH levels lasting for up to
90 minutes [28], and accordingly, the endogenous GHtion (P , 0.05), whereas no differences were seen on
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Fig. 3. Mean kidney insulin-like growth factor I (IGF-I) levels (A) and
kidney weight (B) over seven days in nonoperated controls (h), sham-
operated animals ( ), uninephrectomized animals treated with placebo
( ), or G120K-PEG (j). Values are mean 6 sem (N 5 6 in each
group). *P , 0.05; **P , 0.01 vs. all other groups.
was fully abolished in G120K-PEG–treated nephrec-
tomized animals (Fig. 3A).Fig. 2. Mean serum growth hormone (GH; A), insulin-like growth
factor I (IGF-I; B), and IGF binding protein 3 (IGFBP-3; C ) levels in
Kidney weight, glomerular volume, and liver weightnonoperated controls (h), sham-operated animals ( ), uninephrectom-
ized animals treated with placebo ( ), or G120K-PEG (j). Values The kidney weight increase in the untreated unine-are mean 6 sem (N 5 6 in each group).
phrectomized group over the study period amounted to
28% after seven days when compared with sham-operated
controls (P , 0.01). The kidney weight increase was fully
abolished in the G120K-PEG–treated uninephrectomizedlevels given in Figure 2A are stimulated values. No differ-
ences in serum GH levels were seen in response to uni- animals (Fig. 3B). The increase in glomerular volume in
untreated uninephrectomized animals amounted to 42%nephrectomy per se, and furthermore, no effect of G120K-
PEG administration was seen (Fig. 2A). In addition, at day 7 when compared with sham-operated controls
(P , 0.01), whereas the glomerular volume of G120K-serum IGF-I and IGFBP-3 were unchanged in all groups
over time with no effect of G120K-PEG treatment (Fig. PEG–treated uninephrectomized mice was fully abol-
ished with a value comparable with the two control2 B, C). Kidney IGF-I increased transiently in placebo-
treated uninephrectomized animals on day 2 (32%, P , groups (Fig. 4). No difference in liver weight was found
on day 7 between sham-operated, placebo-treated, or0.05) when compared with sham-operated controls, with
a decrease on day 7 to a level not significantly different G120K-PEG–treated uninephrectomized animals (S,
1130 6 46 mg; NP, 1131 6 36 mg; NA, 1150 6 51 mg).from controls (Fig. 3A). The increase in kidney IGF-I
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Fig. 4. Mean glomerular volume on day 0 in nonoperated controls (h)
and on day 7 in sham-operated animals ( ), uninephrectomized animals
treated with placebo ( ) or G120K-PEG (j). Values are mean 6 sem
(N 5 6 in each group). *P , 0.05 vs. all other groups.
Kidney GHR, GHBP, and IGF-I mRNAs
Figure 5 shows the renal expression of GHR, GHBP,
and IGF-I over the study period of seven days. GHR/
GHBP mRNA levels were unchanged over time in sham-
operated animals, whereas a decrease was observed in the
untreated uninephrectomized group at day 7 (P , 0.01).
No decrease in GHR/GHBP mRNA levels was observed
in G120K-PEG–treated uninephrectomized animals (Fig.
5). Kidney IGF-I mRNA decreased in untreated uni-
nephrectomized mice at day 7 (P , 0.01), whereas in
G120K-PEG–treated uninephrectomized animals, it de-
creased both at days 2 and 7 (both P , 0.01; Fig. 5).
DISCUSSION
The major new finding of this study is an inhibitory
effect on CRG of an exogenously administered specific
GHR antagonist in adult uninephrectomized mice, thereby
Fig. 5. Mean kidney growth hormone receptor (GHR) mRNA (A),
indicating a strictly permissive role of GH in CRG. GH-binding protein (GHBP) mRNA (B), and insulin-like growth factor
I (IGF-I) (C ) mRNA levels over seven days in nonoperated controlsFor decades, GH and IGFs have been suggested as
(h), sham-operated animals ( ), uninephrectomized animals treatedpathogenic factors in CRG following unilateral nephrec-
with placebo ( ), or G120K-PEG (j). Values are mean 6 sem (N 5
tomy [1–10]. The first indirect evidence for this hypothe- 6 in each group). **P , 0.01 vs. other groups; *P , 0.01 vs. sham-
operated group.sis was presented in the 1970s by the observation that
the CRG response was blunted in uninephrectomized,
hypophysectomized rats [1, 2]. In addition, adult rats
exposed to unilateral nephrectomy have been shown to
GH and IGFs may play in various pathophysiologicalexert increased GH pulsatility [10], and furthermore, the
conditions (for example, diabetic kidney disease [17–administration of a long-acting somatostatin analogue
20]), a series of highly specific antagonists of the GH(octreotide) [6] or a GH-releasing factor antagonist [9]
action has been recently developed. The discovery ofhas been shown to abolish the early CRG. Despite the
these new GHR antagonists enabled us to perform amentioned evidence for a pathogenic role of GH in CRG,
study in which the direct role of GH in CRG couldso far the exact role of GH, as a modulating or a strictly
be answered. Initially, when the GHR antagonists werepermissive factor for CRG in adult rodents, has not yet
been resolved. By recognizing the potential role that discovered, it was shown that an alteration of single
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amino acids in the third a-helix of bovine (b) GH (residues adult rats from different laboratories [3, 5–7]. In this
study, the administration of G120K-PEG completely109 to 126) resulted in a GH antagonist [12–14, 16]. In
vitro experiments showed that the group of GH antago- prevented the obligatory early rise in kidney IGF-I along
with the morphological changes (that is, renal size andnists binds to the GHR with the same affinity as native
GH, but in vivo, a phenotypic dwarf animal characterized glomerular volume). This observation is similar to the
effect seen during octreotide administration (a long-act-by low circulating IGF-I levels and a proportional body
composition develops when the GH antagonist is ex- ing somatostatin analogue) in CRG [6]. Although the
transient rise in renal IGF-I peptide seems to be a well-pressed in transgenic mice [15, 16]. Accordingly, studies
were published describing renoprotective effects of GH recognized phenomenon [3, 5–7], the molecular basis for
the increase is still a matter of dispute [7–10]. A recentantagonists in long-term diabetic transgenic mice that
express GH antagonists (bGH-G119R and hGH-G120R) study reported unchanged renal GHR mRNA levels in
immature and adult rats in response to uninephrectomy[17]. Recently, we showed that the administration of a
pegylated GHR antagonist (G120K-PEG) in experimen- [11]. Although immature rats exposed to unilateral ne-
phrectomy have increased levels of IGF-I, IGF-I recep-tal diabetes in mice abolished renal IGF-I accumulation,
renal enlargement, and glomerular hypertrophy and tor (IGF-IR), and IGF-II/mannose-6-phosphate receptor
(IGF-II/Man-6-PR) mRNA [8], IGF-I mRNA has beendiminished the increase in urinary albumin excretion
through a specific mechanism independent of changes reported to be unchanged [7] or decreased [4, 8, 11]
along with decreased levels of IGF-IR and IGF-II/Man-in body weight, food consumption, metabolic control,
serum GH, IGF-I, or IGFBP-3 [18]. 6-PR mRNA in uninephrectomized adult rats [8, 11]. In
this study, a decrease in renal GHR/GHBP mRNA wasAlong with this observation we demonstrate, in this
study, inhibition of CRG and glomerular hypertrophy seen in untreated uninephrectomized animals at day 7
when the renal growth rate had abated. In contrast, noin uninephrectomized mice treated with G120K-PEG for
one week. The animals received G120K-PEG subcutane- decrease in renal GHR/GHBP mRNA was observed in
G120K-PEG–treated animals, which most likely reflectsously every second day to maintain high diurnal levels
[18]. No toxic effects of G120K-PEG treatment were a compensatory response at mRNA level to the func-
tional GHR blockade induced by the GHR antagonist.observed, as treated mice had similar changes in body
weight and food consumption when compared with their In concert with previous studies, kidney IGF-I mRNA
was decreased in nephrectomized animals at day 7,placebo-treated group. As observed in the diabetes study
mentioned earlier in this article [18], the renal effects whereas G120K-PEG treatment induced a modest, but
still significant, decrease in IGF-I mRNA at day 2, alongof GHR antagonism were observed without detectable
changes in circulating GH, IGF-I, or IGFBP-3 levels, with inhibition of the early rise in kidney IGF-I peptide.
In conclusion, the administration of a GHR antagonistindicating a specific effect of G120K-PEG through a
blockade of the renal GHR. This is further supported in uninephrectomized adult mice has an inhibitory effect
on increased kidney IGF-I, CRG, and glomerular hyper-by the fact that the increase in kidney IGF-I observed in
untreated diabetic animals was fully abolished in G120K- trophy, without affecting circulating levels of GH, IGF-I,
or IGFBP-3. Accordingly, the mechanism of the renalPEG–treated animals. Finally, the weight of a reference
organ (that is, the liver) was unaffected by GHR antago- effects of the GHR antagonist may be mediated through
an inhibitory effect on renal IGF-I accumulation throughnist treatment.
As stated earlier in this article, unilateral nephrectomy the renal GHR. This study demonstrates the central role
of the GH/IGF axis in CRG and shows, to our knowledgein adult rats has been characterized by increased GH-
pulsatility [10]. However, in this study, we were unable for the first time, the strictly permissive role of GH in
the process in adult mice.to demonstrate changes in barbital stimulated GH levels
in uninephrectomized mice after two and seven days
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